Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 4
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Trace Metal Impurities Effects on the Formation of [64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM).
Shinada M, Suzuki H, Hanyu M, Igarashi C, Matsumoto H, Takahashi M, Hihara F, Tachibana T, Sogawa C, Zhang MR, Higashi T, Sato H, Kurihara H, Yoshii Y, Doi Y. Shinada M, et al. Among authors: igarashi c. Pharmaceuticals (Basel). 2023 Dec 21;17(1):10. doi: 10.3390/ph17010010. Pharmaceuticals (Basel). 2023. PMID: 38275997 Free PMC article.
Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer.
Yoshii Y, Tashima H, Iwao Y, Yoshida E, Wakizaka H, Akamatsu G, Yamaya T, Matsumoto H, Yoshimoto M, Igarashi C, Hihara F, Tachibana T, Zhang MR, Nagatsu K, Sugyo A, Tsuji AB, Higashi T. Yoshii Y, et al. Among authors: igarashi c. Sci Rep. 2020 Mar 10;10(1):4143. doi: 10.1038/s41598-020-61056-5. Sci Rep. 2020. PMID: 32157106 Free PMC article.
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study.
Hihara F, Matsumoto H, Yoshimoto M, Masuko T, Endo Y, Igarashi C, Tachibana T, Shinada M, Zhang MR, Kurosawa G, Sugyo A, Tsuji AB, Higashi T, Kurihara H, Ueno M, Yoshii Y. Hihara F, et al. Among authors: igarashi c. Int J Mol Sci. 2022 May 22;23(10):5807. doi: 10.3390/ijms23105807. Int J Mol Sci. 2022. PMID: 35628616 Free PMC article.
Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET.
Matsumoto H, Igarashi C, Tachibana T, Hihara F, Shinada M, Waki A, Yoshida S, Naito K, Kurihara H, Ueno M, Ito K, Higashi T, Yoshii Y. Matsumoto H, et al. Among authors: igarashi c. Pharmaceutics. 2022 Sep 12;14(9):1928. doi: 10.3390/pharmaceutics14091928. Pharmaceutics. 2022. PMID: 36145676 Free PMC article.
Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography.
Matsumoto H, Igarashi C, Tachibana T, Hihara F, Waki A, Zhang MR, Yoshida S, Naito K, Kurihara H, Ueno M, Ito K, Higashi T, Yoshii Y. Matsumoto H, et al. Among authors: igarashi c. Pharmaceutics. 2021 Dec 28;14(1):67. doi: 10.3390/pharmaceutics14010067. Pharmaceutics. 2021. PMID: 35056963 Free PMC article.
Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy.
Yoshimoto M, Yoshii Y, Matsumoto H, Shinada M, Takahashi M, Igarashi C, Hihara F, Tachibana T, Doi A, Higashi T, Fujii H, Washiyama K. Yoshimoto M, et al. Among authors: igarashi c. Pharmaceutics. 2021 Oct 16;13(10):1706. doi: 10.3390/pharmaceutics13101706. Pharmaceutics. 2021. PMID: 34683999 Free PMC article.
12 results